Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ: SRPT), expressing a variety of opinions spanning from bullish to bearish. The table below ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics SRPT, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Stay up-to-date on Wall Street's latest analyst calls, stock downgrades, and upgrades for major companies like Sarepta, Cisco, and more.

Sarepta shares dropped 27% after the first death in March. BMO lowered its price target to $70, warning of risks to 2025 revenue guidance and potential regulatory action affecting non-ambulatory ...

One thing we could say about the analysts on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts ...

Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne ...